Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy

Stiborova, Katerina; Treggiari, Elisabetta; Amores-Fuster, I.; Busto, I. del; Killick, David; Maddox, Thomas W.; Marrington, Mary; Mason, Sarah; Blackwood, Laura

doi:10.1111/jsap.13047

Cited by 4 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…a prospective multicenter study with a combination of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine MCT and concluded that this protocol is a viable treatment option for unresectable MCTs, is well-tolerated and effective in most dogs, with response rates and durations higher than those reported for toceranib as a single treatment agent for MCT. Stiborova et al [ 188 ] evaluated the toxicity related to the combination of radiotherapy with vinblastine chemotherapy and concluded that the combination is safe and did not increase chemotherapy-related myelosuppression as a single treatment.…”

Section: Therapeutic Approachmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Nardi

Horta

Fonseca-Alves

et al. 2022

Cells

View full text Add to dashboard Cite

Mast cell tumors (MCTs) are hematopoietic neoplasms composed of mast cells. It is highly common in dogs and is extremely important in the veterinary oncology field. It represents the third most common tumor subtype, and is the most common malignant skin tumor in dogs, corresponding to 11% of skin cancer cases. The objective of this critical review was to present the report of the 2nd Consensus meeting on the Diagnosis, Prognosis, and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors, which was organized by the Brazilian Association of Veterinary Oncology (ABROVET) in August 2021. The most recent information on cutaneous and subcutaneous mast cell tumors in dogs is presented and discussed.

show abstract

Section: Therapeutic Approachmentioning

confidence: 99%

“…TT has been the subject of studies mainly in the United States and Europe, with positive results, tolerable toxicity, ease of administration, and being capable of promoting adequate local tumor control [ 188 , 189 , 190 , 191 , 192 , 193 ]. The application of TT in felines is contraindicated.…”

Section: Therapeutic Approachmentioning

confidence: 99%

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Nardi

Horta

Fonseca-Alves

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…Knowledge on incidence of sAE essentially comes from clinical trials that focused only on a single molecule or protocol. In these studies, description of AE is heterogeneous and evaluation of overall incidence of AE is beyond their scope 6–33 . The largest retrospective study dealing with overall frequency of AE included 292 cases, with digestive and haematological AE occurring in 20%–22% of dogs, 83% of which were grade 1 toxicities.…”

Section: Introductionmentioning

confidence: 99%

Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs

Chavalle

Chamel

Denoeux³

et al. 2021

Vet Comparative Oncology

View full text Add to dashboard Cite

Overall prevalence of severe adverse events (sAE) has been poorly studied in veterinary medicine and peer‐reviewed studies mostly focused on a single protocol, making it difficult to have a general overview. The aim of this retrospective study was to assess the frequency and risk factors of sAE secondary to various protocols of chemotherapy in dogs. Medical records of 155 dogs receiving chemotherapy between January 2013 and December 2018 were reviewed. Adverse events (AE) were graded according to Veterinary Comparative Oncology Group‐common terminology criteria for AE (VCOG‐CTCAE) grading system. Statistical analyses were performed to determine whether demographic, cancer type and chemotherapy protocol were associated with development of sAE and their consequences. AE were reported at least once in 124 (80%) dogs and sAE were observed in 50 (32.3%) dogs. Among them, 23 (14.8%) had gastro‐intestinal and 31 (20.0%) had myelotoxic events. sAE led to hospitalisation in 37 (23.9%) dogs, to chemotherapy arrest in 12 (7.7%) dogs and to euthanasia or death in 9 (5.8%) dogs. Haematopoietic tumours were statistically associated with a higher frequency of sAE (p = .004), gastrointestinal sAE (p = .009) and hospitalisation (p = .004). A body weight over 10 kg was associated with less haematological sAE (p < .001). The use of a multi‐agent protocol was highlighted as a risk factor for sAE (p = .038) and haematological sAE (p < .001). sAE following chemotherapy and leading to hospitalisation, chemo arrest or death were relatively common. A special attention during chemotherapy follow‐up should be given to small dogs and those receiving multi‐agent protocol or treated for haematopoietic tumours.

show abstract

The influences of alkaloids of Chelidonium majus L., Colchicum autumnale L, Catharanthus roseus (L.) G.Don and Vinca minor L. on malignant neoplasms, the review of modern researches.

Pavlenko,

Strokina

2023

USMYJ

View full text Add to dashboard Cite

natural alkaloids of Chelidonium majus L., Colchicum autumnale L. and Catharanthus roseus (L.) G.Don are anticancer agents. Some of them, such as colchicine, vincristine and vinblastine, are used in modern medicine, as chemotherapy medicines against malignant neoplasms, some of them are effective supplement to conventional methods or works to prevent cancer onset (chelidonine, sanguinarine, chelerythrine, protopine and allocryptopine). The effect of mitotic poisons that are alkaloids of Colchicum autumnale colchicine, Catharanthus roseus vincristine and vinblastine against malignant neoplasms began to be studied in the last century, the fact of mitotic spindle violation is given in a large number of works. However, the mechanisms of apoptosis under their influence have been little studied. The alkaloids of Chelidonium majus and Vinca minor L. have been much less studied, both in clinical studies and experimental ones, including insufficiently researched their anti-proliferative action, the ability to cause apoptosis and its possible mechanism. The research of apoptosis mechanisms caused by natural antitumor agents, will allow creating more effective and saving medicines based on the active ingredients of plant raw materials in the future. The aim of the paper was the analysis of the effect of the main alkaloids of Chelidonium majus, Colchicum autumnale, Catharanthus roseus and Vinca minor on malignant neoplasms and the mechanisms of such an influence with the help of analytic review of foreign and Ukrainian literature for the period 2002-2023 using medical database PubMed. The researched data obtained on cell lines, laboratory animals (in vitro) and clinic studies were analyzed. According to the analysis of the literature of recent years, the cytotoxic and anti-proliferative effects of natural alkaloids of Chelidonium majus chelidonine, Colchicum autumnale colchicine, Catharanthus roseus vincristine and vinblastine and Vinca minor vincamine on malignant neoplasms can be considered proven. Colchicine caused apoptosis in high doses, chelidonine, on the contrary, caused apoptosis of malignant cells in relatively low doses; in large doses it caused autophagy. The signaling pathways of apoptosis mechanisms of malignant cells under the influence of chelidonine, colchicine, vincristine, vinblastine and vincamine are much less studied and require additional research. Most of the results support the mitochondrial pathway, but there is a view in favor of the receptor-mediated pathway. The medicine, which contained alkaloids of Chelidonium majus, showed a positive effect when used in combination with conventional antitumor therapy. Chelidonium majus and Vinca minor alkaloids are candidates for their use in antitumor therapy, but clinical studies of these agents are insufficient.

show abstract

Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy

Cited by 4 publications

References 36 publications

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors

Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs

The influences of alkaloids of Chelidonium majus L., Colchicum autumnale L, Catharanthus roseus (L.) G.Don and Vinca minor L. on malignant neoplasms, the review of modern researches.

Contact Info

Product

Resources

About